GLP-1 Drug Shortage Looms as Deadline to Halt Off-Brand Production Approaches

Strategic Insights -

Tens of thousands of patients in the United States who have come to rely on compounded GLP-1 medications for weight loss and diabetes treatment are facing uncertainty as a federal deadline approaches to halt the sale and production of off-brand products. The shortage, which began in 2022 due to increased demand, has led to a reliance on compounded products, but the FDA's restriction on these products is set to tighten this week. Manufacturers have been preparing for the transition, but experts warn that the restrictions could create new strain on the overall supply.

Key Takeaways:

  • Over 70,000 people per week, including Michelle Pierce, have been using compounded GLP-1 drugs to manage weight and diabetes.
  • The FDA declared that shortages of tirzepatide and semaglutide had ended, but experts warn that restrictions on compounded products could add new strain to the supply.
  • Dr. Jody Dushay, an endocrinologist at Beth Israel Deaconess Medical Center, expressed concerns about the safety and efficacy of compounded GLP-1 products, but acknowledges that restrictions may lead to a situation similar to when GLP-1 injections first became popular.
  • Patients who have been relying on compounded products may start to seek out new prescriptions from providers like Dr. Dushay, potentially creating increased pressure on the starting doses of tirzepatide and semaglutide.
  • The FDA's restriction on compounded GLP-1 products comes as concerns about existing shortages are bubbling, with FDA declaring that shortages of tirzepatide and semaglutide had ended when the drug manufacturers' "stated product availability and manufacturing capacity can meet the present and projected national demand."
  • A Lilly spokesperson stated that Zepbound and Mounjaro are "fully available" for patients, and entering the market, "Mass-compounded tirzepatide, like "personalized," "tailored" or something similar, is breaking the law and putting patients at risk."
  • The Outsourcing Facilities Association, which represents large-scale compounding pharmacies known as 503Bs, filed lawsuits against the FDA about the "sudden removal" of tirzepatide and semaglutide from the drug shortage list, but the judge in both cases ruled to allow the FDA plan to block compounded products to continue.

Statistics:

  • Over 70,000 people per week have been using compounded GLP-1 drugs from Olympia Pharmaceuticals.
  • 40% of Olympia Pharmaceuticals' production is dedicated to GLP-1 products.
  • The FDA declared that shortages of tirzepatide and semaglutide had ended when the drug manufacturers' "stated product availability and manufacturing capacity can meet the present and projected national demand."
  • Upwards of 50% of patients in the country may qualify for employer benefits for medication, but insurance coverage is hampering accessibility.

Sources:

  • Deidre McPhillips, CNN
  • Michelle Pierce, patient using compounded semaglutide injections
  • Josh Fritzler, chief financial officer of Olympia Pharmaceuticals
  • Dr. Jody Dushay, endocrinologist at Beth Israel Deaconess Medical Center
  • Lee Rosebush, chairman of the Outsourcing Facilities Association
  • Novo Nordisk
  • Eli Lilly
  • Dr. Disha Narang, endocrinologist and director of obesity medicine at Endeavor Health